Minerva Neurosciences (NERV) awards options tied to Phase 3 trial
Rhea-AI Filing Summary
Minerva Neurosciences, Inc. reported that director Inderjit Kaul received a grant of 12,147 stock options to purchase common stock at an exercise price of $3.97 per share, expiring on August 2, 2036. All 12,147 options are reported as directly held after the grant.
Vesting is performance- and time-based: 25% vests on November 14, 2026; 45% vests on the tenth day after a public announcement that a Phase 3 confirmatory trial of roluperidone in schizophrenia met its primary endpoint at 12 weeks; and the remaining 30% vests on the tenth day after public announcement of safety data from the 40-week relapse assessment phase, in each case while Kaul provides services under a consulting agreement dated November 14, 2025.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Kaul Inderjit
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) F1 | 12,147 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 12,147 shares (Direct)
Footnotes (1)
- F1. 25% of the option shall vest on November 14, 2026; an additional 45% of the Consultant Option shall vest on the tenth day following the date of the Company's public announcement that it has achieved, on a statistically significant basis, the primary endpoint of its Phase 3 confirmatory trial of roluperidone in schizophrenia at the 12-week timepoint; and the remaining 30% of the Consultant Option shall vest on the tenth day following the date of the Company's public announcement of safety data from the 40-week relapse assessment phase; provided, however, in each case, that the Reporting Person is providing services pursuant to that certain consulting agreement dated November 14, 2025 on each such vesting date.
Key Figures
Options granted: 12147.0000 options
Exercise price: $3.9700 per share
Expiration date: 2036-08-02
+3 more
6 metrics
Options granted
12147.0000 options
Stock Option (right to buy) granted to director Inderjit Kaul
Exercise price
$3.9700 per share
Exercise price for the stock options on Minerva common stock
Expiration date
2036-08-02
Option expiration date for the granted stock options
Time-based vesting portion
25%
Vests on November 14, 2026, subject to continued consulting services
Primary endpoint vesting portion
45%
Vests after public announcement that Phase 3 roluperidone trial met primary endpoint
Safety data vesting portion
30%
Vests after public announcement of safety data from 40-week relapse assessment phase
Key Terms
Stock Option (right to buy), Phase 3 confirmatory trial, primary endpoint, relapse assessment phase, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
Phase 3 confirmatory trial medical
"primary endpoint of its Phase 3 confirmatory trial of roluperidone"
primary endpoint medical
"that it has achieved, on a statistically significant basis, the primary endpoint"
The primary endpoint is the single main result a clinical study is designed to measure to decide if a treatment works, like the finish line in a race that tells you who won. Investors care because meeting or missing this goal drives regulatory decisions, future sales expectations and stock value — it turns trial data into a clear yes-or-no signal about a drug’s commercial prospects.
relapse assessment phase medical
"safety data from the 40-week relapse assessment phase"
consulting agreement financial
"services pursuant to that certain consulting agreement dated November 14, 2025"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What stock option grant did Minerva Neurosciences (NERV) report for Inderjit Kaul?
Minerva Neurosciences reported a grant of 12,147 stock options to director Inderjit Kaul at an exercise price of $3.97 per share, expiring on August 2, 2036. All options relate to the company’s common stock and are reported as directly held.
How do the new NERV stock options for Inderjit Kaul vest?
The options vest in three tranches: 25% on November 14, 2026; 45% on the tenth day after a public announcement that a Phase 3 roluperidone trial met its primary endpoint; and 30% after a public announcement of 40-week safety data.
What performance conditions affect Inderjit Kaul’s Minerva Neurosciences (NERV) option vesting?
Two tranches are tied to clinical milestones: 45% vests after a public announcement that a Phase 3 confirmatory trial of roluperidone in schizophrenia achieved its primary endpoint, and 30% vests after a public announcement of safety data from the 40-week relapse assessment phase.
Is continued service required for Inderjit Kaul’s NERV options to vest?
Yes. Each vesting event is conditioned on Kaul providing services under a consulting agreement dated November 14, 2025 on the applicable vesting date. If he is not providing services then, the related tranche does not vest under these terms.
What is the exercise price and term of the Minerva Neurosciences (NERV) options granted?
The granted options have an exercise price of $3.97 per share and an expiration date of August 2, 2036. This gives a multi-year window to exercise any portion that becomes vested under the time- and performance-based conditions.